Medical Center Saint Naum EOOD — Clinical Trial Site

20 Registered trials

8 Currently recruiting

Organisation

Medical Center Saint Naum EOOD

Location

Sofiya, Bulgaria

Identifier

ORG-100043883

Address

Ulitsa D-R Lyuben Rusev 1, 1113, Bulgaria

Departments

-
Clinic for intensive care of Neurological diseases
Medical Center Saint Naum EOOD
N/A
NA
Psychiatry

Clinical trials at this site (20)

Search interface

Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Pending

2024-519994-20-00 Agitation Associated with Alzheimer’s Disease 5
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) - X-CE… Pending

2025-522775-29-00 Depressive episodes associated with Bipolar disorder I 5
An Open-label Study of Azetukalner in Bipolar I or II Depression Pending

2025-522872-10-00 Depressive episodes associated with Bipolar disorder I 5
ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) Recruiting

2025-521711-39-00 Lewy body Dementia psychosis (LBDP) 5 2026-05-17
Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519423-24-00 Major Depressive Disorder 5 2025-10-07
ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) Recruiting

2025-521710-25-00 Lewy Body Dementia Psychosis (LBDP) 4 2025-12-04
A study to assess the efficacy and safety of ITI-1284 as adjunctive treatment in patients with Generalized Anxiety Disorder Recruiting

2024-513302-56-00 Generalized Anxiety Disorder 4 2025-11-17
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting

2025-520613-31-00 Agitation Associated with Alzheimer’s Disease 5 2025-10-31
Study to assess the efficacy and safety of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519420-25-00 Major Depressive Disorder 5 2025-10-22
A study to measure how well seltorexant works in adult depressed patients and how safe it is both for short- and long-term use when taken wi… Recruiting

2023-509070-36-00 Major Depressive Disorder with Insomnia Symptoms 5 2025-03-18
A study to see how well KarXT is tolerated and how well tolerated it is when taken for long time in participants with psychosis associated w… Recruiting

2023-504151-27-00 Psychosis associated with Alzheimer’s Disease 5 2024-05-09
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy a… Ended

2024-513104-34-00 Major Depressive Disorder 4 2024-11-25
A study to test different doses of BI 1569912 in people with depression who take anti-depressive medicine Ended

2023-507942-10-00 Major depressive disorder 4 2024-07-31
A Clinical Study that will measure how well SEP-363856 works and how safe it is in adults with Generalized Anxiety Disorder Ended

2022-502077-42-00 generalised anxiety disorder 10 2023-09-14
A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression. Ended

2023-508163-74-00 Major Depressive Disorder 5 2023-06-12
A rollover study for subjects that complete KAR-012 trial, to assess Long-term Safety and Tolerability of Adjunctive KarXT in Subjects with … Ended

2024-510773-20-00 Schizophrenia 5 2023-06-12
Protocol Lay Person Short Title: A Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment o… Ended

2022-500538-27-00 Adjunctive therapy to antidepressants for the treatmen 10 2023-03-30
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) Ended

2024-510770-25-00 Schizophrenia 5 2023-03-22
A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran… Ended

2023-503793-20-00 Prevention of ischemic stroke in patients post acute no 5 2023-01-18
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia Ended

2023-508433-14-00 Schizophrenia 5 2022-09-30